Proof of principle for bevacizumab activity in desmoid-type fibromatosis

Conclusions This is the first report on single agent bevacizumab in DF, which showed both, good tolerability and efficacy in our patient, thereby warranting future trials in DF.

http://link.springer.com/10.1186/s13569-016-0045-3

Source: Clinical Sarcoma Research - April 3, 2016 Category: Cancer & Oncology Source Type: research